COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase 1b Trial of Magrolimab Monotherapy Or Magrolimab In Combination With Azacitidine In Patients With Hematological Malignancies

Protocol No
Principal Investigator
Guru Subramanian Guru Murthy
Hu5F9-G4 is a type of protein called an antibody. It is designed to target and block a protein called CD47. CD47 is present on cancer cells and is used by cancer cells to help protect themselves from your body’s immune system. CD47 is also present on some normal cells including red blood cells. Blocking CD47 with Hu5F9-G4 may enable your body’s immune system to find and destroy the cancer cells.
The purpose of this study is to test the safety of Hu5F9-G4 alone, or in combination with azacitidine in patients with blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Other purposes of this study are to determine the best dose of Hu5F9-G4, the quantity of Hu5F9-G4 in your blood, the side effects it has on your body, and whether or not it can improve your cancer.
Participating Institutions
Froedtert Hospital